APOE and Alzheimer disease: Linear mixed-effects analysis showed that both APOE4 genotype and a baseline AD-RAI > 0.5 could predict faster yearly decline of memory (APOE-ε4 status: P = 0.005; AD-RAI: P < 0.001) and executive ability (APOE-ε4 status: P = 0.042; AD-RAI: P = 0.007) and a faster increase of dementia severity (APOE-ε4 status: P = 0.029; AD-RAI: P < 0.001) over 15 years.